Literature DB >> 11576530

Slotoxin, alphaKTx1.11, a new scorpion peptide blocker of MaxiK channels that differentiates between alpha and alpha+beta (beta1 or beta4) complexes.

J Garcia-Valdes1, F Z Zamudio, L Toro, L D Possani, L D Possan.   

Abstract

A novel peptide from Centruroides noxius Hoffmann scorpion venom was isolated and sequenced. The 37 amino acid peptide belongs to the charybdotoxin sub-family (alphaKTx1) and was numbered member 11. alphaKTx1.11 has 75% sequence identity with iberiotoxin and 54% with charybdotoxin. alphaKTx1.11 revealed specificity for mammalian MaxiK channels (hSlo), thus, was named slotoxin. Slotoxin blocks the MaxiK pore-forming alpha subunit reversibly (K(d)=1.5 nM). Slotoxin association with alpha+beta (beta1 or beta4) channels was approximately 10 times slower than iberiotoxin and charybdotoxin, leading to a lack of effect on alpha+beta4 when tested at 100 nM for 5 min. Thus, slotoxin is a better tool to distinguish MaxiK alpha+beta complexes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11576530     DOI: 10.1016/s0014-5793(01)02791-0

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  20 in total

1.  Characterization of a functionally expressed stretch-activated BKca channel cloned from chick ventricular myocytes.

Authors:  Q Y Tang; Z Qi; K Naruse; M Sokabe
Journal:  J Membr Biol       Date:  2003-12-01       Impact factor: 1.843

2.  Calcium-activated and voltage-gated potassium channels of the pancreatic islet impart distinct and complementary roles during secretagogue induced electrical responses.

Authors:  David A Jacobson; Felipe Mendez; Michael Thompson; Jacqueline Torres; Olivia Cochet; Louis H Philipson
Journal:  J Physiol       Date:  2010-07-19       Impact factor: 5.182

3.  Scorpion toxins prefer salt solutions.

Authors:  Azadeh Nikouee; Morteza Khabiri; Lukasz Cwiklik
Journal:  J Mol Model       Date:  2015-10-16       Impact factor: 1.810

Review 4.  Peptide toxins and small-molecule blockers of BK channels.

Authors:  Mu Yu; San-ling Liu; Pei-bei Sun; Hao Pan; Chang-lin Tian; Long-hua Zhang
Journal:  Acta Pharmacol Sin       Date:  2016-01       Impact factor: 6.150

Review 5.  K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.

Authors:  Heike Wulff; Boris S Zhorov
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

6.  KCa1.1 inhibition attenuates fibroblast-like synoviocyte invasiveness and ameliorates disease in rat models of rheumatoid arthritis.

Authors:  Mark R Tanner; Xueyou Hu; Redwan Huq; Rajeev B Tajhya; Liang Sun; Fatima S Khan; Teresina Laragione; Frank T Horrigan; Pércio S Gulko; Christine Beeton
Journal:  Arthritis Rheumatol       Date:  2015-01       Impact factor: 10.995

Review 7.  Big Potassium (BK) ion channels in biology, disease and possible targets for cancer immunotherapy.

Authors:  Lisheng Ge; Neil T Hoa; Zechariah Wilson; Gabriel Arismendi-Morillo; Xiao-Tang Kong; Rajeev B Tajhya; Christine Beeton; Martin R Jadus
Journal:  Int Immunopharmacol       Date:  2014-07-12       Impact factor: 4.932

Review 8.  Targeting BK (big potassium) channels in epilepsy.

Authors:  Prosper N'Gouemo
Journal:  Expert Opin Ther Targets       Date:  2011-09-19       Impact factor: 6.902

9.  Conopeptide Vt3.1 preferentially inhibits BK potassium channels containing β4 subunits via electrostatic interactions.

Authors:  Min Li; Shan Chang; Longjin Yang; Jingyi Shi; Kelli McFarland; Xiao Yang; Alyssa Moller; Chunguang Wang; Xiaoqin Zou; Chengwu Chi; Jianmin Cui
Journal:  J Biol Chem       Date:  2014-01-07       Impact factor: 5.157

10.  Smooth muscle relaxation and activation of the large conductance Ca(++)-activated K+ (BK(Ca)) channel by novel oestrogens.

Authors:  J Maher; A C Hunter; J G Mabley; J Lippiat; M C Allen
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.